What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese.
· Intro 0:11
· In this episode 0:21
· 2023: current status and controversies 0:35
· What is going on with COVID-19? 01:53
· What do we know about vaccine responses? What should we be telling our patients about vaccines in our immunocompromised population? 2:58
· Lancet Rheumatology MELODY study summary 3:08
· What about patients within the rheumatic and autoimmune disease space? 4:15
· Who is immunocompromised and why does it matter? 5:11
· What is the immunosuppression we are giving them? 6:39
· What to tell patients about getting vaccinated 8:56
· Long COVID 10:09
· What is long COVID? 10:26
· JAMA Network Open study on prevalence and characteristics associated with post-COVID conditions 14:19
· In the clinical arena, what should rheumatologists be thinking about? 16:38
· What about pathogenesis? What do we know about the controversies in this area? 18:58
· Autoimmunity: COVID-19 and autoimmune response 20:45
· What about therapies? 22:22
· The next generation of rheum agents: Immunomodulation with neonatal Fc receptor targeting? 24:40
· A question for the rheumatology community: do patients with immune mediated diseases get more long COVID than the control population? 25:40
· In conclusion 27:37
· Thanks for listening 28:38
Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic.
Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB..
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
